CKD (6407) Q3 2026 earnings summary

Executive summary

• Net sales for the nine months ended December 31, 2025, were ¥112,016 million, a decrease of 2.7% year-over-year.

• Operating profit declined 9.2% year-over-year to ¥12,510 million, and ordinary profit fell 9.4% to ¥12,737 million.

• Profit attributable to owners of parent was ¥8,838 million, down 6.7% year-over-year.

• Comprehensive income rose to ¥14,132 million, up 46.3% year-over-year, driven by gains in other comprehensive income.

• The global economy remained uncertain, but semiconductor-related capital investment, especially for generative AI, showed signs of recovery.

Financial highlights

• Gross profit for the period was ¥32,482 million, compared to ¥33,439 million the previous year.

• Basic earnings per share for the nine months was ¥132.28, down from ¥141.91 year-over-year.

• Total assets increased to ¥218,019 million from ¥210,867 million at the previous fiscal year-end.

• Net assets rose to ¥145,749 million, with an equity-to-asset ratio of 66.9%.

Outlook and guidance

• Full-year net sales forecast is ¥151,000 million, up 3.0% year-over-year.

• Operating and ordinary profit are both forecast at ¥16,600 million, down 12.7% and 13.4% year-over-year, respectively.

• Profit attributable to owners of parent is projected at ¥11,200 million, down 17.2% year-over-year.

• Basic earnings per share for the full year is forecast at ¥167.63.

• No changes have been made to the previously announced forecasts or exchange rate assumptions.